Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/30/2018 |
| Start Date: | June 2007 |
| End Date: | October 7, 2015 |
Previous experience with antibody therapy in both NHL and CLL warrants further exploration of
new antibody treatments for these diseases.
Immunomedics has developed hLL1 (previously designated EPB-1), which is a CDR-grafted, fully
humanized monoclonal antibody specifically targeting CD74.38 The human IgG1 backbone for hLL1
is the same as hLL2 (epratuzumab), a monoclonal antibody whose safety has been demonstrated
in clinical trials of patients with B-cell malignancies and autoimmune disorders.
This is a Phase I, open-label, study conducted in patients with recurrent non-Hodgkin's
lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who have progressed after at least one
prior standard treatment. All patients will receive hLL1 administered intravenously once
daily Monday through Friday of each of 2 consecutive weeks (10 total doses.) Patients will be
assigned to a cohort for hLL1 treatment dose assignment (escalating doses of hLL1 per
statistical plan) in order to determine the maximum tolerated dose (MTD) for this
administration schedule.
new antibody treatments for these diseases.
Immunomedics has developed hLL1 (previously designated EPB-1), which is a CDR-grafted, fully
humanized monoclonal antibody specifically targeting CD74.38 The human IgG1 backbone for hLL1
is the same as hLL2 (epratuzumab), a monoclonal antibody whose safety has been demonstrated
in clinical trials of patients with B-cell malignancies and autoimmune disorders.
This is a Phase I, open-label, study conducted in patients with recurrent non-Hodgkin's
lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who have progressed after at least one
prior standard treatment. All patients will receive hLL1 administered intravenously once
daily Monday through Friday of each of 2 consecutive weeks (10 total doses.) Patients will be
assigned to a cohort for hLL1 treatment dose assignment (escalating doses of hLL1 per
statistical plan) in order to determine the maximum tolerated dose (MTD) for this
administration schedule.
Inclusion Criteria:
- Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or
diagnosis of recurrent chronic lymphocytic leukemia
- Patient has received at least one prior treatment with standard chemotherapy and at
least one prior treatment with rituximab (negative HAHA test required if received
prior humanized antibody treatment)
- Patient has not received anti-cancer therapy within 28 days of treatment unless
disease progression has been demonstrated and toxicities from prior therapy have
resolved
- Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative
analyses (paraffin or frozen, recent or archived)
- Measurable disease as defined by a tumor mass > 1.5 cm in one dimension or WBC > 5,000
(CLL patients)
- Age > 18 years
- Patient has KPS > 50%
- Absolute granulocyte count > 1000 cells/mm3
- Platelet count > 50,000 cells/mm3
- Creatinine < 2.0 x ULN
- Total bilirubin < 2.0 x ULN
- Patient agrees to use birth control if of reproductive potential
- Patient has signed IRB-approved informed consent
Exclusion Criteria:
- Known central nervous system (CNS) involvement by lymphoma
- Known HIV disease
- Patient is pregnant or nursing
- Patient is receiving other investigational drugs
- Known serum human anti-human antibodies (HAHA)
- Estimated life expectancy of < 3 months
We found this trial at
1
site
Click here to add this to my saved trials
